Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when DTIL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrecision BioSciences files routine disclosure for DMD program webcast with KOLs
Filed March 17, 2026 · Period ending March 17, 2026 · ~1 min read
Key Changes
-
low
Company hosting March 17 webcast featuring key opinion leaders to discuss Duchenne muscular dystrophy treatment landscape and PBGENE-DMD program, including FUNCTION-DMD Phase 1/2 trial overview.
Item 7.01 verify on EDGAR → -
low
Filed presentation materials for the KOL event; disclosure is procedural investor relations activity with no material business developments announced.
Item 9.01 verify on EDGAR →
Summary
Precision BioSciences filed an 8-K to disclose a scheduled webcast featuring key opinion leaders discussing Duchenne muscular dystrophy and the company's PBGENE-DMD gene editing program. The March 17 event will include a pediatric neurologist from Arkansas Children's Hospital and the founding president of Parent Project Muscular Dystrophy, alongside company management. This is a routine investor relations disclosure with no material business impact.
The filing simply announces an educational webcast and includes the accompanying presentation materials. For retail holders, this represents standard corporate communication about an ongoing clinical program rather than a significant development requiring immediate attention. Watch for actual clinical trial data or regulatory updates from the FUNCTION-DMD Phase 1/2 trial as meaningful catalysts.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Precision BioSciences filed presentation materials for a PBGENE-DMD Key Opinion Leader event; no material business impact disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Precision BioSciences, Inc. PBGENE-DMD KOL Event presentation materials.
The company filed presentation materials related to a Key Opinion Leader event for PBGENE-DMD, its Duchenne muscular dystrophy gene editing program. This is a routine disclosure of investor or medical community presentation content with no specific business event or financial impact announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify